geometric – Page 4 – Communicable Diseases Research

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

COVID-19 퇴치를 위한 항바이러스 펩티드 기반 SARS-CoV-2 불활성화제의 가능성

Article

Published on 2022-06-032022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 치료제,

ScanNet: an interpretable geometric deep learning model for structure-based protein binding site prediction

Research

Published on 2022-05-302022-10-05
Journal: Nature methods [Category] COVID19(2023년), SARS, 변종,

[키워드] binding site deep learning geometric Protein
[DOI] 10.1038/s41592-022-01490-7 [Article Type] Research

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

건강한 일본 성인을 대상으로 한 NVX-CoV2373(TAK-019) 백신의 안전성 및 면역원성: I/II상 무작위 대조 시험 중간 보고

Clinical Trial

Published on 2022-05-262022-09-12
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] 95% confidence interval Adults adverse event AEs age AMED anti-SARS-CoV-2 immune response antibody ARMS company conducted COVID-19 Data analysis demonstrated development dose enrolled evaluated Follow-up geometric healthy IgG immune response immunogenicity injection injection site pain Interim Japan Japanese Japanese adults Limited NVX-CoV2373 occurred outcome participant Participants pharmaceutical Placebo placebo-controlled trial Protein Randomized Randomized controlled trial receive reported robust Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nanoparticle vaccine SARS-CoV-2 vaccine screened second dose seroconversion rate serum IgG stratified subject Takeda vaccination Vaccine
[DOI] 10.1016/j.vaccine.2022.04.035 PMC 바로가기 [Article Type] Clinical Trial

Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac

CoronaVac을 투여받은 성인에서 피내 경로를 통한 AZD1222의 추가 투여 후 면역원성 및 반응성

Article

Published on 2022-05-262022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] 95%CI administration anti-S anti-SARS-CoV-2 IgG Anti-spike antibody Antibody Response Antibody responses Antibody titer AstraZeneca AZD1222 Blister booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine cohort study common completion CoronaVac CoronaVac vaccine COVID-19 vaccine COVID-19 vaccines delta variant determine dose Endpoint Erythema evaluated geometric geometric mean geometric mean ratios GMRs healthy IgG immunogenicity Immunoglobulin Immunoglobulin G immunologic response injection Intradermal Local median age neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer occurred participant participated primary endpoint proportion prospective cohort study RBD IgG reactogenicity recipient reported resource SARS-CoV-2 vaccine surrogate virus neutralization test sVNT systemic reactogenicity variant Viral Virus neutralization was collected wild type
[DOI] 10.1016/j.vaccine.2022.04.067 PMC 바로가기 [Article Type] Article

Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

네덜란드 의료 종사자의 4가지 다른 SARS-CoV-2 백신에 의해 유도된 SARS-CoV-2 변이체에 대한 항체 반응: 전향적 코호트 연구

Article

Published on 2022-05-172022-09-11
Journal: PLoS Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] Ad26 Ad26.COV2.S Adenovirus adenovirus vector-based vaccines adjusted age and sex Alpha Analysis Antibody Response Antibody titers AZD1222 Beta BNT162b2 booster booster vaccination cellular immunity COV2.S Delta Effectiveness Fold change followed by Gamma geometric geometric mean geometric mean titers GMT group groups head Head-to-head comparison Health care Health care worker highest include initial lack limitation linear mixed model Linear regression mRNA mRNA vaccine mRNA vaccines mRNA-1273 Netherlands neutralization neutralize Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers of BNT162b2 omicron Omicron variant performed prospective cohort prospective cohort study recipient recipients recognize reduction in SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants sera serum vaccination Vaccine variant VoC VOCs was performed was reduced wild-type
[DOI] 10.1371/journal.pmed.1003991 PMC 바로가기 [Article Type] Article

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

BNT162b2 및 CoronaVac 백신으로 회복된 COVID-19 환자 중 Omicron 변이체에 대한 혈청 중화 활성 증가

Article

Published on 2022-05-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] Analysis Antibody test Beta Beta variant BNT162b2 characteristic CoronaVac country COVID-19 Cutoff Delta delta variant detectable determine dose evade geometric geometric mean greater Immunity Inactivated vaccine individual induce Infection Live virus Michael mRNA vaccine NAb titer Neutralizing activity neutralizing antibody of BNT162b2 omicron Omicron variant prospective cohort study Protein receiver receiver operating characteristic Receptor binding recipient recovered COVID-19 patient Recovered COVID-19 patients Reinfection Richard risk SARS-CoV-2 Sensitivity and specificity seropositive serum Serum neutralizing antibody significantly higher spike Spike protein Spike protein receptor binding domain statistically subgroup analysis surrogate Surrogate neutralizing antibody test vaccination Vaccine variant variants virus with COVID-19
[DOI] 10.1016/j.ebiom.2022.103986 PMC 바로가기 [Article Type] Article

The puzzling mutational landscape of the SARS-2-variant Omicron

SARS-2 변종 오미크론의 수수께끼 같은 돌연변이 환경

Article

Published on 2022-05-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘,

[키워드] ACE-2 receptor affected antibody antibody susceptibility association cleavage site Complete coronavirus decrease deletions delta variant dissemination electrostatic Epitopes Evolution explain geometric human population immunological Infection initial initial assessment insertion less molecular mechanism molecular mechanisms mutations N-terminal domain neutralizing epitope neutralizing epitopes NTD omicron Omicron variant parameter Pathogenesis pathogenic phenotype predicted RBD Receptor-binding domain SARS Coronavirus SARS-CoV-2 variant Spike protein surface potential the receptor-binding domain Transmission Vaccine variant Virological virulence virus virus classification
[DOI] 10.1002/jmv.27577 PMC 바로가기 [Article Type] Article

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

불활성화 백신 2회 투여 후 성인에서 AZD1222의 저용량 대 표준 용량의 추가 용량에 대한 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-04-202022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] 95% CI Adults anti-S anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG. Anti-spike antibody Antibody titer ARMS AstraZeneca AZD1222 baseline booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine completion conducted CoronaVac CoronaVac vaccine delta variant dose double-blinded enrolled evaluate Fever geometric geometric mean geometric mean ratio Geometric means GMR GMRs healthy IgG immunogenicity inactivated Inactivated vaccine Infection IQR low dose low-dose median age median interval myalgia neutralization test neutralizing antibody Neutralizing antibody titer participant Prevent Randomized randomized clinical trial randomized, controlled trial RBD IgG reactogenicity receive recipient S-RBD SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly lower Standard dose surrogate surrogate virus neutralization test sVNT systemic reactogenicity the SARS-CoV-2 variant Viral Viral particles virus neutralization test wild type
[DOI] 10.1016/j.vaccine.2022.03.036 PMC 바로가기 [Article Type] Randomized Controlled Trial

The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19

항-C5a 항체 빌로벨리맙은 중증 COVID-19 환자에서 C5a를 효율적으로 억제합니다

Article

Published on 2022-04-012022-09-11
Journal: Clinical and translational science [Category] 임상, 진단,

[키워드] 1:1 Activation adaptive Analysis anaphylatoxin C5a antibody assigned benefit best Blood C3a C5a cause Chain Reaction Coagulation Coagulation system Concentration control group coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia demonstrated drug concentration enzyme favor geometric geometric mean IFX-1 Infection infection site inhibit IQR leads median monoclonal antibody monocyte Monocytes neutrophil Neutrophils oxidative Patient plasma polymerase chain polymerase chain reaction Randomly ranged real-time polymerase chain reaction receive releases reported Result Safe Sample secondary outcome severe coronavirus disease severe COVID-19 Severe COVID-19 pneumonia supportive care suppressed suppression tissue damage Trial vilobelimab
[DOI] 10.1111/cts.13213 PMC 바로가기 [Article Type] Article

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

건강한 성인에서 코로나백 3차 접종의 면역원성 및 안전성, 2회 접종 일정의 면역 지속성: 2건의 단일 센터, 이중 맹검, 무작위, 위약 대조 임상 2상 임상 시험의 중간 결과

Clinical Trial

Published on 2022-04-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] 1:1 95% CI Abstract Administered Adverse reaction analysed antibody Antibody titre assigned Beijing booster dose China clinical trial clinical trials Cohort cohorts Concentration CoronaVac country Cutoff declined development dose doses double-blind eligible foundation GenBank accession number generate geometric geometric mean titre GMIs GMT GMTs groups healthy immune memory immune persistence immune response immunogenicity Inactivated vaccine increase increase in injection Jiangsu material natural neutralising antibody neutralising antibody titre Older outcome participant per-protocol population phase 2 trial Placebo placebo group placebo-controlled positive Program protocol amendment randomised Randomly recalled receive Registered reported resulting SARS-CoV-2 Science second dose Serious Adverse Event seropositive severity significantly increased technology threshold translation Trial vaccination vaccination against COVID-19 vaccination schedule Vaccine virus strain
[DOI] 10.1016/S1473-3099(21)00681-2 PMC 바로가기 [Article Type] Clinical Trial